CN113440478A - Eye care solution - Google Patents
Eye care solution Download PDFInfo
- Publication number
- CN113440478A CN113440478A CN202110747901.7A CN202110747901A CN113440478A CN 113440478 A CN113440478 A CN 113440478A CN 202110747901 A CN202110747901 A CN 202110747901A CN 113440478 A CN113440478 A CN 113440478A
- Authority
- CN
- China
- Prior art keywords
- care solution
- distilled water
- eye care
- eyes
- trioxane
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 45
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 30
- 238000002156 mixing Methods 0.000 claims abstract description 29
- 239000012153 distilled water Substances 0.000 claims abstract description 26
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 claims abstract description 16
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims abstract description 16
- 235000011187 glycerol Nutrition 0.000 claims abstract description 16
- 229940041616 menthol Drugs 0.000 claims abstract description 16
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 16
- 239000001301 oxygen Substances 0.000 claims abstract description 16
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract description 12
- BGJSXRVXTHVRSN-UHFFFAOYSA-N 1,3,5-trioxane Chemical compound C1OCOCO1 BGJSXRVXTHVRSN-UHFFFAOYSA-N 0.000 claims abstract 7
- 230000003204 osmotic effect Effects 0.000 claims description 10
- 239000007788 liquid Substances 0.000 claims description 7
- 239000012528 membrane Substances 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 7
- 238000001914 filtration Methods 0.000 claims description 6
- 230000001954 sterilising effect Effects 0.000 claims description 6
- 230000001502 supplementing effect Effects 0.000 claims description 6
- 239000000919 ceramic Substances 0.000 claims description 2
- 230000005611 electricity Effects 0.000 claims description 2
- 238000000034 method Methods 0.000 claims description 2
- 230000003068 static effect Effects 0.000 claims description 2
- 238000003756 stirring Methods 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 10
- 210000002919 epithelial cell Anatomy 0.000 abstract description 7
- 208000003556 Dry Eye Syndromes Diseases 0.000 abstract description 5
- 206010013774 Dry eye Diseases 0.000 abstract description 5
- 230000036285 pathological change Effects 0.000 abstract description 5
- 231100000915 pathological change Toxicity 0.000 abstract description 5
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 abstract description 3
- 230000001590 oxidative effect Effects 0.000 abstract description 3
- 239000000243 solution Substances 0.000 description 30
- KQBSGRWMSNFIPG-UHFFFAOYSA-N trioxane Chemical compound C1COOOC1 KQBSGRWMSNFIPG-UHFFFAOYSA-N 0.000 description 12
- 210000004379 membrane Anatomy 0.000 description 6
- 238000001514 detection method Methods 0.000 description 5
- 210000003560 epithelium corneal Anatomy 0.000 description 5
- -1 oxygen radicals Chemical class 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 4
- 239000003637 basic solution Substances 0.000 description 4
- 238000004140 cleaning Methods 0.000 description 4
- 210000004087 cornea Anatomy 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 230000000474 nursing effect Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 3
- 230000004438 eyesight Effects 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 208000001860 Eye Infections Diseases 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- 230000003796 beauty Effects 0.000 description 2
- 230000005779 cell damage Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 208000011323 eye infectious disease Diseases 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 210000001747 pupil Anatomy 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 208000003322 Coinfection Diseases 0.000 description 1
- 208000028006 Corneal injury Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000020564 Eye injury Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000003443 Unconsciousness Diseases 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000003464 asthenopia Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000027734 detection of oxygen Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 210000005081 epithelial layer Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Ophthalmology & Optometry (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
An eye care solution is prepared by mixing menthol, glycerin, trioxane and distilled water, wherein each 10ml of the distilled water contains: 8.9-9.5 mg of menthol, 0.15-0.2 ml of glycerol and 50-51 ml of trioxane; the eye care solution has the effects of relieving dry eyes and unsmooth eyes and moistening the eyes, and on the other hand, the eye care solution supplies oxygen to the eyes through ozone with strong dissolving capacity and strong oxidizing capacity, so that a proper amount of oxygen free radicals of the eyes are ensured, corneal epithelial cells are protected, and pathological changes of the corneal epithelial cells are prevented.
Description
Technical Field
The invention relates to the field of eye care solutions, and particularly relates to an eye care solution.
Background
At present, science and technology are rapidly developed, and television, computers, ipads and mobile phones are full of lives of people, so that the problems of dry eyes, unsmooth eyes and the like caused by excessive eye use are solved, and the eyesight is further reduced. In addition, people have more varied ways to pursue beauty, such as wearing beauty pupils, contact lenses, and the like. The use of cosmetic pupils or contact lenses prevents the eyes from contacting the outside air, thereby reducing the effective oxygen-capturing time of the eyes, which ultimately leads to hypoxia of the eyes. Under the state of oxygen deficiency, corneal epithelium is pathologically changed and damaged, the mitosis process of cells is delayed, the number of cells is reduced, the epithelial layer is thinned, epithelial cells are easy to peel off due to enzyme dysfunction, and symptoms such as dry eyes, acid swelling of eyes, blurred vision and the like are easy to cause, even the vision is degraded.
Pathological changes of the corneal epithelium mean that the barrier function of the corneal epithelium is destroyed or the integrity of the corneal epithelium is damaged for various reasons, resulting in partial or complete loss of the epithelium. At the same time, inflammatory reactions may also occur, possibly even resulting in corneal stromal lesions that affect vision.
Clinically, it is known that only 15% of the oxygen supply to the cornea of the eye comes from the respiratory system, and the other 85% is obtained by contact with the outside air. Therefore, the lack of oxygen radicals is one of the important causes of discomfort in the eye and pathological changes in the corneal epithelium. Therefore, increasing oxygen radicals is one of the efficacy needs of eye washing care products.
Cellular damage by oxygen radicals is caused by peroxidation of polyunsaturated fatty acids and/or decomposition products of lipid peroxides in biological membranes. Clinically, the detection of oxygen free radical cells and oxygen free radicals is mainly realized through MDA detection and SOD activity detection, and the two detection modes belong to indirect detection. The data detected by MDA represents the lipid peroxidation degree in the organism and indirectly represents the cell damage degree; the detection of SOD activity indirectly reflects the clearance of the substrate for oxygen free radical
In addition, clinically, patients who are unconscious or sedated in intensive care units lose moisture and corneal injury due to long-term corneal exposure, and patients who are bedridden and have systemic infection are combined, so that the probability of secondary infection of eyes is increased, and the secondary eye injury is caused. Therefore, antibacterial is one of the efficacy requirements of eye cleaning and caring products.
The current way to relieve eye fatigue is to let the eyes rest; or hot compress and cold compress are alternated and repeated for several times; or the eye cleaning and nursing lotion for moistening and cleaning eyes is used, but the existing eye cleaning and nursing lotion in the market only has the function of temporarily moistening the cornea, has short action time, and can possibly cause inflammatory reaction after being used for multiple times in short time, thereby aggravating the uncomfortable feeling of the eyes. Therefore, how to find new drugs for treating the common symptoms of ophthalmology has become a hotspot and difficulty in the current research of ophthalmology.
Disclosure of Invention
The invention aims to provide an eye care solution.
In order to achieve the purpose, the invention provides the following technical scheme:
an eye care solution is prepared by mixing menthol, glycerin, trioxane and distilled water, wherein each 10ml of the distilled water contains: 8.9-9.5 mg of menthol, 0.15-0.2 ml of glycerol and 50-51 ml of trioxane.
Further, the distilled water is triple distilled water.
A preparation method of an eye care solution comprises the following steps: putting 8.9-9.5 mg of menthol and 0.15-0.2 ml of glycerol into distilled water, stirring and mixing, supplementing distilled water to 10ml, introducing 50ml of trioxane, mixing by using a gas-liquid mixing device, and filtering and sterilizing by using a 0.2 mu m membrane to obtain the care solution.
Further, after the mixing is finished, the pH value of the nursing liquid is adjusted to 7.2-7.4. The pH value is adjusted to be proper, so that the nursing effect is prevented from being influenced.
Further, after the mixing is completed, the osmotic pressure of the care solution is adjusted to 240-290 mOsm/L. Is convenient for the absorption of eye tissues.
Further, the preparation method of the trioxane is as follows: high-voltage static electricity generated by surface discharge of high-frequency ceramic is utilized to ionize oxygen molecules in the air near the electrode, and the oxygen is generated in a short time.
Compared with the prior art, the invention has the beneficial effects that: the eye care solution has the effects of relieving dry eyes and unsmooth eyes and moistening the eyes, and on the other hand, the eye care solution supplies oxygen to the eyes by ozone with strong dissolving capacity and strong oxidizing capacity, so that the corneal epithelial cells are protected while a proper amount of oxygen free radicals of the eyes are ensured, and the pathological change of the corneal epithelial cells is prevented; the eye care solution prepared by the invention has the effects of resisting and inhibiting bacteria of eyes, preventing eye infection and inhibiting inflammation, and therefore, the eye care solution can also be used as a clinical medicine.
Detailed Description
The technical solutions in the embodiments of the present invention will be clearly and completely described below, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
Example 1: 10mL of triple distilled water is taken as a basic solution, which contains 9.1mg of menthol, 0.2mL of glycerol and 50.4mL of trioxane, the pH value is 7.2-7.4, and the osmotic pressure is 240-290 mOsm/L.
The preparation method comprises the following steps: dissolving 0.2mL of glycerol and 9.1mg of menthol in the triple distilled water solution, uniformly mixing, supplementing the triple distilled water solution to 10mL, and fully mixing by adopting a high-efficiency gas-water turbine mixer. Then adding 50.4m L of trioxane, adopting a gas-liquid mixing device for full mixing, adjusting the pH value to be 7.2-7.4 and the osmotic pressure to be 240-290mOsm/L, and filtering and sterilizing by a 0.2 mu m membrane to obtain the eye care solution.
Example 2: 10mL of triple distilled water is taken as a basic solution, which contains 9.5mg of menthol, 0.18mL of glycerol and 51mL of trioxane, the pH value is 7.2-7.4, and the osmotic pressure is 240-290 mOsm/L.
The preparation method comprises the following steps: dissolving 0.18mL of glycerol and 9.5mg of menthol in the triple distilled water solution, uniformly mixing, supplementing the triple distilled water solution to 10mL, and fully mixing by adopting a high-efficiency gas-water turbine mixer. Adding 51ml of trioxane, fully mixing by adopting a gas-liquid mixing device, adjusting the pH value to 7.2-7.4 and the osmotic pressure to 240-200 mOsm/L, and filtering and sterilizing by a 0.2 mu m membrane to obtain the eye care solution.
Example 3: 10mL of triple distilled water is taken as a basic solution, which contains 8.9mg of menthol, 0.15mL of glycerol and 50mL of trioxane, the pH value is 7.2-7.4, and the osmotic pressure is 240-290 mOsm/L.
The preparation method comprises the following steps: dissolving 0.15mL of glycerol and 8.9mg of menthol in the triple distilled water solution, uniformly mixing, supplementing the triple distilled water solution to 10mL, and fully mixing by adopting a high-efficiency gas-water turbine mixer. And adding 50ml of trioxane, fully mixing by adopting a gas-liquid mixing device, adjusting the pH value to 7.2-7.4 and the osmotic pressure to 240-280 mOsm/L, and filtering and sterilizing by using a 0.2 mu m membrane to obtain the eye care solution.
Example 4: 10mL of triple distilled water is taken as a basic solution, which contains 9mg of menthol, 0.2m L of glycerol and 50.4 of trioxane, 50.4m L of pH value between 7.2 and 7.4 and the osmotic pressure of 240-290 mOsm/L.
The preparation method comprises the following steps: dissolving 0.2mL of glycerol and 9mg of menthol in the triple distilled water solution, uniformly mixing, supplementing the triple distilled water solution to 10mL, and fully mixing by adopting a high-efficiency gas-water turbine mixer. Adding 50.4ml of trioxane, fully mixing by adopting a gas-liquid mixing device, adjusting the pH value to 7.2-7.4 and the osmotic pressure to 240-290mOsm/L, and filtering and sterilizing by a 0.2 mu m membrane to obtain the eye care solution.
The MDA and SOD activity assay was performed according to the different concentrations of the care solutions of examples 1-4, using physiological saline, and blank control rats without any product.
Dynamic changes in SOD activity in corneal tissue
Note: h and # P > 0.05
TABLE 1
Dynamic variation of MDA content in corneal tissue
P and # p > 0.05;
▲and is 0.05
TABLE 2
As can be seen from tables 2 and 3, the oxygen supply effect of the product on the cornea of the eye is remarkable, and the cornea tissue can be effectively protected.
Has the advantages that: the eye care solution has the effects of relieving dry eyes and unsmooth eyes and moistening the eyes, and on the other hand, the eye care solution supplies oxygen to the eyes by ozone with strong dissolving capacity and strong oxidizing capacity, so that the corneal epithelial cells are protected while a proper amount of oxygen free radicals of the eyes are ensured, and the pathological change of the corneal epithelial cells is prevented; the eye care solution prepared by the invention has the effects of resisting and inhibiting bacteria of eyes, preventing eye infection and inhibiting inflammation, and therefore, the eye care solution can also be used as a clinical medicine.
The foregoing is a more detailed description of the present invention that is presented in conjunction with specific embodiments, and the specific embodiments of the present invention should not be considered limited to the foregoing description. It will be apparent to those skilled in the art that several simple deductions or substitutions can be made to the above embodiments without departing from the inventive concept, the scope of which is defined by the appended claims and their equivalents.
Claims (6)
1. An eye care solution, which is prepared by mixing menthol, glycerin, trioxane and distilled water, wherein each 10ml of the distilled water contains: 8.9-9.5 mg of menthol, 0.15-0.2 ml of glycerol and 50-51 ml of trioxane.
2. The eye care solution according to claim 1, wherein the distilled water is triple distilled water.
3. The preparation method of the eye care solution is characterized by comprising the following steps: putting 8.9-9.5 mg of menthol and 0.15-0.2 ml of glycerol into distilled water, stirring and mixing, supplementing distilled water to 10ml, introducing 50ml of trioxane, mixing by using a gas-liquid mixing device, and filtering and sterilizing by using a 0.2 mu m membrane to obtain the care solution.
4. The eye care solution of claim 3, wherein the pH of the solution is adjusted to 7.2 to 7.4 after mixing.
5. The eye care solution according to claim 3, wherein the osmotic pressure of the solution is adjusted to 240-290mOsm/L after the mixing.
6. The eye care solution according to claim 3, wherein the trioxane is prepared by the following method: high-voltage static electricity generated by surface discharge of the high-frequency ceramic is utilized to ionize oxygen molecules in the air near the electrode to generate the trioxane.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110747901.7A CN113440478A (en) | 2021-07-02 | 2021-07-02 | Eye care solution |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110747901.7A CN113440478A (en) | 2021-07-02 | 2021-07-02 | Eye care solution |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113440478A true CN113440478A (en) | 2021-09-28 |
Family
ID=77814815
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110747901.7A Pending CN113440478A (en) | 2021-07-02 | 2021-07-02 | Eye care solution |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113440478A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101467961A (en) * | 2007-12-26 | 2009-07-01 | 上海汇康生物科技有限公司 | Nourishing and moisture-keeping type eye-nursing liquid and prescription |
| CN107456508A (en) * | 2017-01-19 | 2017-12-12 | 山东福瑞达生物工程有限公司 | A kind of eye care solution and preparation method and application |
| CN110755465A (en) * | 2019-11-04 | 2020-02-07 | 海昌隐形眼镜有限公司 | Eye care solution and preparation method and application thereof |
| CN112535690A (en) * | 2019-09-20 | 2021-03-23 | 邓丽 | Oxygen supply and sterilization integrated ozone eye cleaning and nursing lotion |
-
2021
- 2021-07-02 CN CN202110747901.7A patent/CN113440478A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101467961A (en) * | 2007-12-26 | 2009-07-01 | 上海汇康生物科技有限公司 | Nourishing and moisture-keeping type eye-nursing liquid and prescription |
| CN107456508A (en) * | 2017-01-19 | 2017-12-12 | 山东福瑞达生物工程有限公司 | A kind of eye care solution and preparation method and application |
| CN112535690A (en) * | 2019-09-20 | 2021-03-23 | 邓丽 | Oxygen supply and sterilization integrated ozone eye cleaning and nursing lotion |
| CN110755465A (en) * | 2019-11-04 | 2020-02-07 | 海昌隐形眼镜有限公司 | Eye care solution and preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111632075B (en) | Exosome preparation for promoting skin wound healing and preparation method thereof | |
| CN107714504A (en) | A kind of same human-like collagen composition and its applied in cosmetics | |
| CN103405592A (en) | Bacteriostatic water-soluble personal lubricant and preparation method thereof, and condom | |
| CN104644754A (en) | Traditional Chinese medicine preparation for alleviating visual fatigue and application thereof | |
| US7655255B2 (en) | Topical composition for transdermal administration | |
| CN104840485A (en) | Active carbon suppository for treating cervical erosion, and preparation method thereof | |
| CN108904760A (en) | It is a kind of for the antibacterial liquid of gynaecological imflammation and its preparation method of aerosol | |
| CN108992451A (en) | A kind of emulsifiable paste and preparation method thereof with anti-inflammatory anti-itch antibiotic effect | |
| CN112006958A (en) | Depilatory cream and preparation method thereof | |
| CN113499354A (en) | Eye lotion | |
| CN113440478A (en) | Eye care solution | |
| US8758836B2 (en) | Method and formulation for treating dry ear inflammation with cortisone | |
| US20080181919A1 (en) | Shiunko nanomicell for skin treatment and preparation method for the same | |
| WO2024011868A1 (en) | Use of vanillyl butyl ether in preparation of products for treating dandruff and tinea corporis | |
| CN103520708A (en) | Composition capable of promoting wound healing and reducing scarring | |
| CN112535690A (en) | Oxygen supply and sterilization integrated ozone eye cleaning and nursing lotion | |
| CN112022902A (en) | Preparation method and application of carbon-point modified fluconazole eucalyptus oil microemulsion gel | |
| CN105560074A (en) | Toothpaste | |
| CN105193686A (en) | Female care solution and preparation method thereof | |
| CN111870590B (en) | Liquid acne-removing patch and preparation method thereof | |
| CN107898806A (en) | A kind of composition and its application with strong anti-inflammatory activity | |
| CN109432204B (en) | Silver ion spray and preparation method thereof | |
| WO1981000723A1 (en) | Medicines for skin | |
| CN103830303B (en) | A kind of compositions of pre-counteracting bedsores | |
| CN105902686A (en) | In-situ gel eyewash containing nano-carbon crystals and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210928 |